Phase 2 N=61 A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
Kidney Transplantation
Primary: Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 6 — 1; 4; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,094 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease — 362.7; 429.1; 420.2; 200.9 titer
Phase 1 N=200 Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
Influenza
Primary: Number of Subjects With Solicited Local Symptoms. — 48; 48; 1; 0 subjects
N/A N=42 Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants Who Responded — 7; 4 participants
N/A N=30 Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model
Pre-hospital Ventilation
Primary: Tidal Volume — 341.8; 27.5; 604.1 milliliters (mL) — p=<0.0001
Phase 2 N=74 Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Head and Neck Cancer
Primary: Event-free Survival Rate at 1 Year — 0.79 proportion of patients
Phase 2 N=112 Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Chronic Primary Insomnia
Primary: Mean Wake Time After Sleep Onset (WASO) — 109.1; 98.7; 90.0; 77.7 minutes — p=0.0018
Phase 2 N=289 Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Dry Eye Disease
Primary: Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 Weeks — 78.3; 76.8; -1.1; -1.7 units on a scale
Phase 2 N=55 Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer — 25; 80 mg/m2
N/A N=28 Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
Moderate to Severe Palmar Plantar Psoriasis
Primary: Percentage of Patients Achieving a Palmar/Plantar PGA Score of 0 or 1 at Week 16. — 0.375 percentage of participants
Phase 2 N=59 Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
Phase 2 N=265 Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
N/A N=117 Cortisol Response to Moderate and Deep Sedation in Children
Adrenal Insufficiency
Primary: Change From Baseline to Peak Salivary Cortisol Level — 2.9; 4.3; 3.3 Number (ratio of peak to baseline)
N/A N=467 Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
Non-Melanoma Skin Carcinoma
Primary: Number of Participants Who Developed Non-Melanoma Skin Cancer (NMSC) — 34; 23 participants — p=0.042
Phase 4 N=150 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4 — 31 percentage of participants